Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 2,108

Human DNA Repair Genes

Wood, R., Mitchell, M., Sgouros, J., & Lindahl, T. (2001) · Science · doi:10.1126/science.1056154 · Cited by 1,719

Galectins as modulators of tumour progression

Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339

Balancing repair and tolerance of DNA damage caused by alkylating agents

Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3185 · Cited by 977

Temozolomide: Mechanisms of Action, Repair and Resistance

Zhang, J., Stevens, M. F. G., & Bradshaw, T. D. (2011) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 951

Regulation of PTEN Transcription by p53

Stambolic, V., MacPherson, D. P., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., & Mak, T. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00323-9 · Cited by 936

Galectin-1: a small protein with major functions

Camby, I., Mercier, M. L., Lefranc, F., & Robert Kiss, A. (2006) · Glycobiology · doi:10.1093/glycob/cwl025 · Cited by 892

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884

Temozolomide and treatment of malignant glioma.

Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722

Alkylation damage in DNA and RNA—repair mechanisms and medical significance

Drabløs, F., Feyzi, E., Aas, P. A., Vågbø, C. B., Kavli, B., Bratlie, M. S., Peña-Dı́az, J., Otterlei, M., Slupphaug, G., & Krokan, H. E. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.05.004 · Cited by 669

MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

Kaina, B., Christmann, M., Naumann, S. C., & Roos, W. P. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 662

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 630

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection

Rubinstein, N., Alvarez, M. J., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 546

Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

Rabinovich, G. A., Baum, L. G., Tinari, N., Paganelli, R., Natoli, C., Liu, F., & Iacobelli, S. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02232-9 · Cited by 527

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Freeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N. L., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 512

NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA

Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442

A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification

Almeida, K. H., & Sobol, R. W. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.01.009 · Cited by 437

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

Yip, S. S. F., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 413

Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation

Paz, A., Haklai, R., Elad‐Sfadia, G., Ballan, E., & Kloog, Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204950 · Cited by 400

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Prados, M. D., Chang, S. M., Butowski, N. A., DeBoer, R. J., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J. R., Rabbitt, J. E., Page, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378

Oncogenic EGFR Signaling Networks in Glioma

Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 371

MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity

Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., & Wang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.009 · Cited by 353

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351

Proliferation of human malignant astrocytomas is dependent on Ras activation

Guha, A., Feldkamp, M. M., Lau, N. C., Boss, G. R., & Pawson, A. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R. M., Kitange, G. J., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 275

The role of poly(ADP-ribose) in the DNA damage signaling network

Malanga, M., & Althaus, F. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-038 · Cited by 274

Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege

Le, Q., Shi, G., Cao, H., Nelson, D. W., Wang, Y., Chen, E. Y., Zhao, S., Kong, C. S., Richardson, D. L., O'Byrne, K. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0206 · Cited by 260

Inhibition of microRNA with antisense oligonucleotides

Esau, C. (2007) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 260

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

Neyns, B., Sadones, J., Joosens, E., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 260

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 251

Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI

Yang, Y.-P., Chien, Y., Chiou, G., Cherng, J., Wang, M., Lo, W., Chang, Y.-L., Huang, P., Chen, Y., Shih, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.071 · Cited by 238

Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas

Lefranc, F., Facchini, V., & Kiss, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1395 · Cited by 237

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

Liu, L., Markowitz, S. D., & Gerson, S. L. (1996) · PubMed · Cited by 235

miR-195, miR-455-3p and miR-10a∗ are implicated in acquired temozolomide resistance in glioblastoma multiforme cells

Ujifuku, K., Mitsutake, N., Takakura, S., Matsuse, M., Saenko, V., Suzuki, K., Hayashi, K., Matsuo, T., Kamada, K., Nagata, I., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.013 · Cited by 230

The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis

Babashah, S., & Soleimani, M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.008 · Cited by 220

Pten signaling in gliomas

Knobbe-Thomsen, C. B., Merlo, A., & Reifenberger, G. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.3.196 · Cited by 203

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 191

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

Narita, Y., Nagane, M., Mishima, K., Huang, H.-J. S., Furnari, F. B., & Cavenee, W. K. (2002) · PubMed · Cited by 189

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

Chakravarti, A., Wang, M., Robins, H. I., Lautenschlaeger, T., Curran, W. J., Brachman, D. G., Schultz, C. J., Choucair, A. K., Dolled-Filhart, M. P., Christiansen, J., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.10.008 · Cited by 178

DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy

Tubbs, J. L., Pegg, A. E., & Tainer, J. A. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.011 · Cited by 175

Degradation of the alkylated form of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase

Xu‐Welliver, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.823 · Cited by 168

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

Lo, H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010037 · Cited by 164

Ras is involved in the negative control of autophagy through the class I PI3-kinase

Furuta, S., Hidaka, E., Ogata, A., Yokota, S., & Kamata, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207539 · Cited by 163

Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

Kaina, B., Margison, G. P., & Christmann, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0491-7 · Cited by 150

Pten signaling in gliomas

Knobbe-Thomsen, C. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-3-196 · Cited by 146

Present and potential future issues in glioblastoma treatment

Lefranc, F., Sadeghi, N., Camby, I., Metens, T., Dewitte, O., & Robert Kiss, A. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.719 · Cited by 145

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy

Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldm036 · Cited by 138

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 135

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis

Rabinovich, G. A., Cumashi, A., Bianco, G. A., Ciavardelli, D., Iurisci, I., DʼEgidio, M., Piccolo, E., Tinari, N., Nifantiev, N. E., & Iacobelli, S. (2005) · Glycobiology · doi:10.1093/glycob/cwj056 · Cited by 124

Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.

Burton, E., Lamborn, K. R., Forsyth, P. A., Scott, J. N., O’Campo, J., Uyehara‐Lock, J. H., Prados, M. D., Berger, M. S., Passe, S. M., Uhm, J. H., et al. (2002) · PubMed · Cited by 121

Galectins and Gliomas

Mercier, M. L., Ensign, S. P. F., Mathieu, V., Robert Kiss, A., & Lefranc, F. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00270.x · Cited by 115

O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

Silber, J. R., Bobola, M. S., Blank, A., & Chamberlain, M. C. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.004 · Cited by 115

Evidence of galectin-1 involvement in glioma chemoresistance☆

Mercier, M. L., Lefranc, F., Mijatovic, T., Debeir, O., Haibe‐Kains, B., Bontempi, G., Decaestecker, C., Robert Kiss, A., & Mathieu, V. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.01.009 · Cited by 106

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

Tanaka, M., Koul, D., Davies, M. A., Liebert, M., Steck, P. A., & Grossman, H. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203918 · Cited by 103

Oncogenic role of microRNAs in brain tumors

Pang, J. C.-S., Kwok, W. K., Chen, Z., & Ng, H.-K. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0525-0 · Cited by 101

Functional evaluation of p53 and PTEN gene mutations in gliomas.

Kato, H., Kato, S., Kumabe, T., Sonoda, Y., Yoshimoto, T., Kato, S., Han, S., Suzuki, T., Shibata, H., Kanamaru, R., et al. (2000) · PubMed · Cited by 98

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol

Combs, S. E., Heeger, S., Haselmann, R., Edler, L., Debus, J., & Schulz–Ertner, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-133 · Cited by 95

The -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain

Miller, M. C., Klyosov, A. A., & Mayo, K. H. (2009) · Glycobiology · doi:10.1093/glycob/cwp084 · Cited by 91

Review of Mammalian DNA Repair and Translational Implications

Hansen, W. K., & Kelley, M. R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38861-5 · Cited by 78

CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration

Bhakat, K. K., & Mitra, S. R. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg086 · Cited by 65

Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency

HORTON, J., & Wilson, S. H. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.10.016 · Cited by 65

Clinical implications of microRNAs in human glioblastoma

Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., & Sasaki, T. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00019 · Cited by 61

The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas

Park, C., Kim, J., Kim, J. Y., Song, S. W., Kim, J. W., Choi, S. H., Kim, T. M., Lee, S., Kim, I. H., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12253 · Cited by 59

Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern

Camby, I., Decaestecker, C., Lefranc, F., Kaltner, H., Gabius, H., & Robert Kiss, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.037 · Cited by 55

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 49

DAVANAT®(GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies

Klyosov, A. A., Zomer, E., & Platt, D. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch004 · Cited by 33

Galectin-1 and immunotherapy for brain cancer

Verschuere, T., Vleeschouwer, S. D., Lefranc, F., Robert Kiss, A., & Gool, S. V. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.40 · Cited by 25

Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair, and p53

Pletsas, D., Garelnabi, E. A. E., Li, L., Phillips, R. M., & Wheelhouse, R. T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401121k · Cited by 24

Synergistic cytotoxicity of the poly ( ADP ‐ribose) polymerase inhibitor ABT ‐888 and temozolomide in dual‐drug targeted magnetic nanoparticles

Muñoz‐Gámez, J. A., López-Viota, M., Barrientos, A., Carazo, Á., Sanjuán‐Nuñez, L., Quiles, R., Muñoz‐de‐Rueda, P., Delgado, Á. V., Ruiz‐Extremera, A., & Salmerón, J. (2014) · Liver International · doi:10.1111/liv.12586 · Cited by 14

Expression and significance of P53 protein and MDM-2 protein in human gliomas.

Wang, A.-L., Liu, Z., Li, G., & Zhang, L. (2011) · PubMed · Cited by 14

[Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].

Zhu, J., Li, Z., Geng, F.-Y., Fu, Q., Guo, C.-J., Xiao, Y.-L., Zhang, Z., & Li, G. (2010) · PubMed · Cited by 8

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 422

New insights into long noncoding RNAs and their roles in glioma

Peng, Z., Liu, C., & Wu, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0812-2 · Cited by 375

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 335

Targeting autophagy to sensitive glioma to temozolomide treatment

Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 306

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261

Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review

Lu, A. (2022) · Glioma · doi:10.4103/glioma.glioma_24_22 · Cited by 2

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 422

Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance

(2026) · Journal of Chemical Biological and Physical Sciences · doi:10.24214/jcbps.a.16.1.09816

Novel strategies to overcome chemoresistance in human glioblastoma

Tang, Q., Ren, T., Bai, P., Wang, X., Zhao, L., Zhong, R., & Sun, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116588 · Cited by 24

Molecular mechanisms in temozolomide-resistant glioblastoma

Lee, S. Y., & Kitange, G. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00029-4 · Cited by 1